

Collagen-binding recombinant fibronectin fragments containing type II domains

Karna Skorstengaard*, Thor L. Holtet, Michael Etzerodt, Hans C. Thøgersen

Laboratory of Gene Expression, Department of Chemistry, University of Aarhus, Gustav Wieds Vej 10, DK-8000 Aarhus, Denmark

Received 3 March 1994

Abstract

Each of the two type II domains and four larger fragments, containing one or two type II domains of fibronectin, have been expressed in *Escherichia coli*. A special vector, containing a fragment encoding the cleavage site for Factor X_a, Ile-Glu-Gly-Arg, inserted immediately before the protein fragment of interest, was used. After treatment of the purified fusion proteins with reduced/oxidized glutathione, the correctly folded fibronectin fragments were released by proteolytic digestion with Factor X_a. The largest fragment, consisting of two type II and two type I domains, was the only fragment able to bind to immobilized gelatin.

Key words: Fibronectin; Type II domains; Gelatin-binding; Refolding; Factor X_a

1. Introduction

Fibronectin (FN) is a large multidomain/multifunctional glycoprotein found in blood plasma and in the extracellular matrix (reviewed in [1]). Its two, almost identical chains are built from three types of repeating units, the type I, type II and type III domains [2,3]. The type II domains, of which there are two, consist of approx. 60 amino acid residues and contain four cysteinyl residues connected in a 1–3, 2–4 disulfide bridge pattern [4]. Type II domains have been identified in other proteins, such as blood clotting factor XII [5], bovine seminal fluid proteins PDC-109 and BSP A3 [6,7], insulin-like growth factor II receptor/mannose 6-phosphate receptor [8,9], mannose receptor [10], 72 kDa and 92 kDa type IV collagenases [11,12]. Five of these seven proteins (two have not been tested) can bind to denatured collagen (gelatin), and the type II domains are believed to play an important role in this binding. The two type II units of FN are unique to the 42 kDa gelatin-binding fragment (GBF) of FN, which also contains four type I domains in the sequence: I₆-II₁-II₂-I₇-I₈-I₉ [4] (numbers refer to the actual domain number, starting from the amino terminus of FN). Subfragments of the 42 kDa GBF (I₆-II₁, II₂-I₇ and I₈-I₉) have been isolated [13,14] in order to further localize the gelatin-binding site. Of these were II₂-I₇ and

I₈-I₉, strongly gelatin-binding and I₆-II₁ was weakly gelatin-binding. Thus, separate gelatin-binding sites may be located on the type I and type II domains of the 42 kDa GBF. Other type II containing fragments of FN have been produced by gene expression in *E. coli*. These are II₁, II₁-II₂ and II₁-II₂-I₇-I₈-I₉, expressed as β -galactosidase fusion proteins [15], and they all bind immobilized gelatin. In contrast, one of the same fragments, II₁-II₂, expressed by others [16], also as a β -galactosidase fusion protein, did not bind gelatin, unless I₇ or the 14 amino terminal residues of I₇ was added to the carboxy-terminus of the fragment.

In the mentioned, more or less conflicting reports, the type II₁ or type II₂ domains were either bound to each other, to a type I domain or to a leader protein. In the present work, we have isolated recombinant type II domains of FN that is free of type I domains and other fragments, and tested their ability to bind immobilized gelatin. Our results show, that only the largest fragment, I₆-II₁-II₂-I₇, was able to bind to immobilized gelatin. None of the smaller fragments, consisting of one or two type II domains, bound to gelatin. The disulfide bridge patterns in the two small fragments, II₁ and II₂a (II₂ with a carboxy-terminal extension) were determined and found to be correct.

2. Materials and methods

2.1. Materials

Restriction enzymes and chymotrypsin were purchased from Boehringer (Mannheim, Germany). A Qiagen kit for plasmid preparation and sequencing kit (ver. 2.0) used for dideoxy sequencing of cloned frag-

*Corresponding author. Fax: (45) (86) 201 222.

Abbreviations: FN, fibronectin; GBF, gelatin-binding fragment; HPLC, high-performance liquid chromatography; FX, plasma factor X; PMSF, phenylmethyl sulfonyl fluoride; NTA, nitrilo-triacetic acid

ments, were from USB (Cleveland, OH, USA). *E. coli* N4830–1 cells were purchased from Pharmacia (Sweden). Ni^{2+} -NTA-Sepharose was synthesized as in [17]. Gelatin was coupled to Sepharose 6B as described [18]. FX was isolated from bovine plasma and activated essentially as described in [19] or purchased from Denzyme, Denmark. Trypsin was purchased from Worthington (Freehold, NJ, USA). Gelatin from swine skin (type I) was from Sigma (Sigma product no: G-2500).

2.2. Plasmids

Plasmid pFH134, containing the cDNA insert of the entire 42 kDa GBF of FN [20], was a kind gift from K. Vibe-Pedersen (Aarhus, Denmark). The *E. coli* expression plasmid pLcIIMLCH6 was constructed from the vector pLcII [19,21] as described in [22].

2.3. Construction of plasmids expressing the fibronectin fragments

DNA fragments encoding six type II containing fragments of FN (I_6 -II₁-II₂-I₇, II₁, II₂, II_{2a} (II₂ with a six residue carboxy-terminal extension peptide), II₁-II₂ and II₂-I₇, see Fig. 1) were amplified from pFH134 by PCR, using the primer pairs shown in Fig. 2. The amplified DNA fragments were purified by electrophoresis on 1% agarose, cleaved by *Bam*HI and *Hind*III and cloned into the *Bam*HI/*Hind*III sites of pLcIIMLCH6. CII encodes the 31 amino terminal residues of the α 2(I) protein, MLC encodes the 118 amino terminal residues of human myosin light chain and H6 codes for six histidines, providing an affinity purification handle for a single-step purification on Ni^{2+} -NTA-Sepharose [17].

2.4. Bacterial expression

E. coli QY13 cells [19] or N4830–1 cells were transformed with the pLcIIMLCH6FXFIB expression vector, containing the inserted fibronectin fragment (FIB) and the factor X_a recognition site, Ile-Gly-Glu-Arg, (FX) introduced by the amino-terminal oligonucleotides used in the PCR reaction (see Fig. 2). The cells were grown at 30°C until $A_{600} = 0.8$ and expression of the fusion protein was induced by heat shock at 42°C (15 min) [19]. Following expression at 37°C for 4–5 h, cells were harvested by centrifugation at 4°C and taken up in equal volumes of 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0 and detergent buffer [19]. Inclusion bodies were then isolated essentially as described [19]. After the final centrifugation the inclusion bodies were resuspended in 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0 and mixed with the same volume of neutralized phenol and then sonicated. Two volumes of ethanol was added to the phenol extract and a crude protein fraction was obtained after centrifugation.

2.5. Purification of the fusion protein

The pellet containing the crude protein was dissolved in 6 M guanidinium chloride, 50 mM Tris-HCl, pH 8.0 containing 100 mM dithiothreitol and incubated overnight at 20°C. Insoluble cellular debris was removed by centrifugation and the solution was gel-filtered on a Sephadex G-25 column, equilibrated with 8 M urea, 1 M NaCl, 0.2 mM ascorbic acid, 50 mM Tris-HCl, pH 8.0 to remove the dithiothreitol. The fractions containing the protein were pooled and applied to a Ni^{2+} -NTA-Sepharose column, equilibrated with the same buffer. Following extensive wash with the same buffer and with 6 M guanidinium chloride, 50 mM Tris-HCl, pH 8.0, the bound fusion protein was eluted with 8 M urea, 1 M NaCl, 0.2 mM ascorbic acid, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0.

2.6. Refolding of the fusion protein

The purified fusion protein was reduced with 25 mM dithiotreitol and gel-filtered on a Sephadex G-25 column, equilibrated with 8 M urea, 1 M NaCl, 2 mM dithiotreitol, 50 mM Tris-HCl, pH 8.0. Ten mM thiopyridyl-glutathione (a blocking agent, reacting with free thiols) was added to the pooled fractions containing the protein, and the mixture was incubated at 4°C overnight with constant stirring. The blocked fusion protein was gel-filtered on a Sephadex G-25 column in 8 M urea, 1 M NaCl, 50 mM Tris-HCl, pH 8.0. The pooled fractions containing the protein were reappplied to the Ni^{2+} -NTA-Sepharose column (in the same buffer) to initiate the refolding on the column. First, 5 ml of 8 M urea, 1 M NaCl, 5 mM ascorbic acid, 50 mM Tris-HCl, pH 8.0 was applied, then extensive wash with 1 M NaCl, 50 mM Tris-HCl, pH 8.7 and incubation overnight in this buffer. The bound fusion protein was eluted with 1 M NaCl, 10 mM EDTA, 50 mM Tris-HCl, pH 8.7 and subjected to disulfide exchange (16 h, 20°C) by addition of reduced/oxidized glutathione at final concentrations of 5 mM/0.5 mM.

2.7. Cleavage with factor X_a

The refolded fusion protein was cleaved with factor X_a (16 h, 20 °C, 1:100; w/w) either directly in the elution buffer from the Ni^{2+} -NTA-Sepharose column, or in 1 M NaCl, 50 mM Tris-HCl, pH 8.0, following gel filtration on Sephadex G-25.

2.8. Affinity chromatography on gelatin-Sepharose

The collagen affinity of the individual type II containing FN fragments was assayed by affinity chromatography on a gelatin-Sepharose column (1.6 × 11 cm), equilibrated with 50 mM Tris-HCl, 0.5 M NaCl, pH 7.5. Bound protein was eluted with 5 M urea, 50 mM Tris-HCl, 0.5 M NaCl, pH 7.5 (Fig. 3A).

2.9. Determination of disulfide bridges

The two small fragments containing domains II₁ and II_{2a}, respectively, were purified by reverse-phase HPLC (Pharmacia LKB HPLC system), on a Vydac C₄ column for II₁ and on a Nucleosil C₁₈ for II_{2a}. SDS-PAGE (according to [23]) or amino terminal protein sequencing (using an Applied Biosystems 477A/120A sequencer) was performed to identify the peaks containing II₁ and II_{2a}, respectively. These were dried down, dissolved in 0.1 M ammonium bicarbonate and digested, first with chymotrypsin (3 h, 37°C, 1:100; w/w) and then with trypsin (3 h, 37°C, 1:200; w/w). Chymotrypsin was inhibited by PMSF and trypsin by soybean trypsin inhibitor. Peptides were separated by HPLC, using a Nucleosil C₁₈ column. Aliquots from each peak were hydrolyzed (6 M HCl, 16 h, 110°C) and the amino acid composition was determined by a modification of the procedure described in [24]. Prior to hydrolyzation, performic acid oxidation was performed [25] to allow identification of cystines as cysteic acid. The bridge-containing peptides were sequenced, further treated with performic acid and rechromatographed by HPLC (Nucleosil C₁₈) to verify the shift from one to two peaks. These peaks were analyzed by amino acid analysis and sequencing.

3. Results and discussion

Six fragments of fibronectin, containing type II domains, have been expressed in *E. coli* as cIIMLCH6FXFIB fusion products, isolated from inclusion bodies, denatured, reduced, purified and refolded/reoxidized. Sequence specific cleavage with FX_a liberated the fibronectin fragments. The six fibronectin fragments are: I_6 -II₁-II₂-I₇, II₁, II₂, II_{2a}, II₁-II₂ and II₂-I₇ (II_{2a} is II₂ with six extra residues (AAHEEI) in the carboxy terminus) and their position in the 42 kDa GBF of FN are




Fig. 1. Location of the six recombinant type II containing fragments, I_6 -II₁-II₂-I₇, II₁, II₂, II_{2a} (II_{2a} is II₂ with a carboxy-terminal extension peptide, AAHEEI), II₁-II₂ and II₂-I₇, in the gelatin-binding 42 kDa fragment of fibronectin.




Fig. 2. Primer pairs used for PCR amplification of DNA fragments encoding the six fibronectin fragments shown in Fig. 1. The corresponding amino acid sequence is shown above each primer. The carboxy-terminal amino acid sequences (the right part) are translated from the strands complementary to the primers. Numbers refer to the protein sequence [2]. Restriction sites are underlined. The arrow indicate the FX_a cleavage site.

shown in Fig. 1. DNA sequencing of the part of pFH134 encoding II₂, showed CGA (coding for arginine, in position 380 of the protein sequence) instead of CAA (coding for glutamine) as reported by Kornblihtt et al. [20]. This brings the human FN sequence [20] in accordance with the bovine FN sequence [2] in this position, resulting in identical type II₂ domains in the two species, indicating that this observed sequence difference is likely to represent an original sequencing error rather than mutation of the cDNA clone.

Affinity chromatography on gelatin-Sepharose showed that only the largest fragment, I₆-II₁-II₂-I₇, bound to gelatin (Fig. 3A). When bound protein was diluted and reapplied to the gelatin-Sepharose column, complete rebinding was observed (Fig. 3B), confirming the specificity of the interaction. None of the smaller fragments bound to the gelatin-Sepharose column. This is in disagreement with the results of Bányai et al. [15], who reported that type II domain containing fragments, II₁ and II₁-II₂, of FN, expressed as β -galactosidase fusion proteins, bind immobilized gelatin. Our findings also disagree with those of Ingham et al. [13,14] and Owens and Baralle [16], who report that the fragment, II₂-I₇, by itself [14], or as a β -galactosidase fusion protein [16], can bind gelatin-Sepharose. The cause for the discrepancy is unresolved, but may relate to different types or sources of




Fig. 3. (A) Affinity chromatography of the fibronectin fragment I₆-II₁-II₂-I₇ on a gelatin-Sepharose column. (B) Rechromatography of diluted, bound protein from Fig. 3A. Arrows indicate the start of elution with buffer containing 5 M urea.

gelatin. Also it could be questioned if our fragments are correctly folded. To test correct folding in two of the smallest fragments, II₁ and II_{2a}, the disulfide bridge patterns were determined, and in both cases found to be correct. One may also speculate if a correct disulfide-bridge pattern is enough to ensure correct folding. We believe it is, and therefore the discrepancy between our results and those of Bányai et al. [15] may rely on un-specific binding of their fragments to the gelatin-Sepharose or on the gelatin source as mentioned.

In conclusion, our results do not support the conclusion of others [15], that one type II domain of fibronectin is capable of binding to gelatin on its own, similar to those of PDC-109 and BSP A3 [6,7]. In contrast, our data suggest that the four-domain cluster I₆-II₁-II₂-I₇ is the smallest type II containing fragment of fibronectin that harbours an authentic binding site for gelatin.

Acknowledgements: We thank Ove Lillelund for technical assistance. This work was supported by grants from The Danish Biotechnology Research Centre Programme and The Danish Cancer Society.

References

- [1] Mosher, D.F. (1980) *Progr. Hemostasis Thromb.* 5, 111–151.
- [2] Skorstengaard, K., Jensen, M.S., Sahl, P., Petersen, T.E. and Magnusson, S. (1986) *Eur. J. Biochem.* 161, 441–453.
- [3] Petersen, T.E., Skorstengaard, K. and Vibe-Pedersen, K. (1989) in: *Fibronectin* (Mosher, D.F., Ed.) pp. 1–24, Academic Press, New York.
- [4] Skorstengaard, K., Thøgersen, H.C. and Petersen, T.E. (1984) *Eur. J. Biochem.* 140, 235–243.
- [5] McMullen, B.A. and Fujikawa, K. (1985) *J. Biol. Chem.* 260, 5328–5341.
- [6] Esch, F.S., Ling, N.C., Bohlen, P., Ying, S.Y. and Guillemin, R. (1983) *Biochem. Biophys. Res. Commun.* 113, 861–867.
- [7] Seidah, N.G., Manjunath, P., Rochemont, J., Sairam, M.R. and Chretien, M. (1987) *Biochem. J.* 243, 195–203.
- [8] Morgan, D.O., Edman, J.C., Standring, D.N., Fried, V.A., Smith, M.C., Roth, R.A. and Rutter, W.J. (1987) *Nature* 329, 301–307.
- [9] Lobel, P., Dahms, N.M., Breitmeier, J., Chirgwin, J.M. and Kornfeld, S. (1987) *Proc. Natl. Acad. Sci. USA* 84, 2233–2237.
- [10] Taylor, M.E., Conary, J.T., Lennartz, M.R., Stahl, P.D. and Drickamer, K. (1990) *J. Biol. Chem.* 265, 12156–12162.
- [11] Collier, I.E., Wilhelm, S.M., Eisen, A.Z., Marmer, B.L., Grant, G.A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E.A. and Goldberg, G.I. (1988) *J. Biol. Chem.* 263, 6579–6587.
- [12] Wilhelm, S.M., Collier, I.E., Marmer, B.L., Eisen, A.Z., Grant, G.A. and Goldberg, G.I. (1989) *J. Biol. Chem.* 264, 17213–17221.
- [13] Ingham, K.C., Brew, S.A. and Migliorini, M.M. (1989) *J. Biol. Chem.* 264, 16977–16980.
- [14] Litvinovich, S.V., Strickland, D.K., Medved, L.V. and Ingham, K.C. (1991) *J. Mol. Biol.* 217, 563–575.
- [15] Bányai, L., Trexler, M., Koncz, S., Gyenes, M., Sipos, G. and Patthy, L. (1990) *Eur. J. Biochem.* 193, 801–806.
- [16] Owens, R.J. and Baralle, F.E. (1986) *EMBO J.* 5, 2825–2830.
- [17] Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. and Stüber, D. (1988) *Bio/Technology* 6, 1321–1325.
- [18] Engvall, E. and Rouslahti, E. (1977) *Int. J. Cancer* 20, 1–5.
- [19] Nagai, K. and Thøgersen, H.C. (1987) *Methods Enzymol.* 153, 461–481.
- [20] Kornblihtt, A.R., Umezawa, K., Vibe-Pedersen, K. and Baralle, F.E. (1985) *EMBO J.* 4, 1755–1759.
- [21] Nagai, K. and Thøgersen, H.C. (1984) *Nature* 309, 810–812.
- [22] Lorenzen, N., Olesen, N.J., Jørgensen, P.V., Etzerodt, M., Holtet, T.L., and Thøgersen, H.C. (1993) *J. Gen. Virol.* 74, 623–630.
- [23] Laemmli, U.K. (1970) *Nature* 227, 680–685.
- [24] Barkholt, V. and Jensen, A.L. (1989) *Anal. Biochem.* 177, 318–322.
- [25] Hirs, C.H.W. (1967) *Methods Enzymol.* 11, 197–199.